Sun Pharmaceutical Industries Limited announced that one of its wholly-owned subsidiaries has entered into an exclusive patent licensing agreement with H. Lundbeck A/S ("Lundbeck") to market and distribute its own version of Vortioxetine in India under the brand name, VORTIDIFTM. The territory of the licensing agreement will only cover India. Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults.

The product is approved in over 80 countries1, including the US, EU, Canada and Australia.